Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Conditions
Recurrent Small Cell Lung Cancer
Conditions: official terms
Small Cell Lung Carcinoma
Conditions: Keywords
recurrent SCLC
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Bendamustin/Ribomustin
Type: Drug
Overall Status
Recruiting
Summary
Determination of response rate Assessment of toxicity and determination of "time to progression"
Detailed Description
Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with histological proven, curative non treatable small lung cell carcinoma

- Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion Criteria:

- Brain metastases

- WHO-PS 3 - 4
Location
Hematology & Oncology Charité CBF Berlin, Germany
Berlin, Germany
Status: Recruiting
Contact: Ulrich Keilholz, MD - +49-30-8445-3596 - ulrich.keilholz@charite.de
Start Date
February 2001
Completion Date
December 2006
Sponsors
Charite University, Berlin, Germany
Source
Charite University, Berlin, Germany
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page